These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 39301552)

  • 1. Association between immune-related adverse events and the prognosis of patients with gastric cancer treated with nivolumab: a meta-analysis.
    Zhang YJ; Tian QY; Wang CE
    Front Oncol; 2024; 14():1408755. PubMed ID: 39301552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: A systematic review and meta-analysis.
    Sun Q; Sun H; Wu N; Hu Y; Zhang F; Cong X
    Front Oncol; 2022; 12():976224. PubMed ID: 36185176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic relevance of immune-related adverse events in lung cancer patients undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis.
    Huang Y; Ma W; Wu D; Lyu M; Zheng Q; Wang T; Zhou J; Liu C
    Transl Lung Cancer Res; 2024 Jul; 13(7):1559-1584. PubMed ID: 39118883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the efficacy and safety of third-line treatments for advanced gastric cancer: A systematic review and network meta-analysis.
    Zhang C; Xiang Y; Wang J; Yan D
    Front Oncol; 2023; 13():1118820. PubMed ID: 36937403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
    Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
    Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
    Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
    Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of inflammatory markers NLR, PLR, and LMR in gastric cancer patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review.
    Tan S; Zheng Q; Zhang W; Zhou M; Xia C; Feng W
    Front Immunol; 2024; 15():1408700. PubMed ID: 39050856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between immune-related adverse events and prognosis in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Ma S; Nie H; Wei C; Jin C; Wang L
    Front Oncol; 2024; 14():1402017. PubMed ID: 38779082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune-related adverse events and their effects on survival outcomes in patients with non-small cell lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Liang Y; Xu H; Liu F; Li L; Lin C; Zhang Y; Wang N; Wang L
    Front Oncol; 2024; 14():1281645. PubMed ID: 38887231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of immune-related adverse events and efficacy in advanced non-small-cell lung cancer: a systematic review and meta-analysis.
    Zhou Y; Chen H; Tang L; Feng Y; Tao Y; Huang L; Lou N; Shi Y
    Immunotherapy; 2023 Feb; 15(3):209-220. PubMed ID: 36710655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are anti-PD-1-associated immune related adverse events a harbinger of favorable clinical prognosis in patients with gastric cancer?
    Zhang X; Xu S; Wang J; Lv Y; Wang N; Lai R; Sha Z; Zhao Q; Guo Z
    BMC Cancer; 2022 Nov; 22(1):1136. PubMed ID: 36335320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis.
    Zhou X; Yao Z; Yang H; Liang N; Zhang X; Zhang F
    BMC Med; 2020 Apr; 18(1):87. PubMed ID: 32306958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognosis of Immune-related Adverse Events in Patients With Advanced Gastric Cancer Treated With Nivolumab or Pembrolizumab: A Multicenter Retrospective Analysis.
    Ando T; Ueda A; Ogawa K; Motoo I; Kajiura S; Nakajima T; Hirano K; Okumura T; Tsukada K; Hara T; Suzuki N; Nakada N; Horikawa N; Fujii T; Yasuda I
    In Vivo; 2021; 35(1):475-482. PubMed ID: 33402499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic relevance of prognostic nutritional indices in gastric or gastro-esophageal junction cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
    Hou S; Song D; Hao R; Li L; Zhang Y; Zhu J
    Front Immunol; 2024; 15():1382417. PubMed ID: 38966640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer: A systematic review and network meta-analysis.
    Chen J; Wang J; Xu H
    Medicine (Baltimore); 2021 Apr; 100(15):e25180. PubMed ID: 33847617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
    Sato K; Akamatsu H; Murakami E; Sasaki S; Kanai K; Hayata A; Tokudome N; Akamatsu K; Koh Y; Ueda H; Nakanishi M; Yamamoto N
    Lung Cancer; 2018 Jan; 115():71-74. PubMed ID: 29290265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic role of the platelet to lymphocyte ratio (PLR) in the clinical outcomes of patients with advanced lung cancer receiving immunotherapy: A systematic review and meta-analysis.
    Zhou K; Cao J; Lin H; Liang L; Shen Z; Wang L; Peng Z; Mei J
    Front Oncol; 2022; 12():962173. PubMed ID: 36059629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab: immortal time bias-corrected analysis.
    Washino S; Shirotake S; Takeshita H; Inoue M; Miura Y; Hyodo Y; Kagawa M; Izumi K; Oyama M; Kawakami S; Saito K; Matsuoka Y; Taniuchi S; Shintani A; Miyagawa T
    Int J Clin Oncol; 2023 Dec; 28(12):1651-1658. PubMed ID: 37658926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort.
    Naqash AR; Ricciuti B; Owen DH; Florou V; Toi Y; Cherry C; Hafiz M; De Giglio A; Muzaffar M; Patel SH; Sugawara S; Burkart J; Park W; Chiari R; Sugisaka J; Otterson GA; de Lima Lopes G; Walker PR
    Cancer Immunol Immunother; 2020 Jul; 69(7):1177-1187. PubMed ID: 32140762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative long-term outcomes of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy as first-line therapy for metastatic non-small-cell lung cancer: a systematic review and network meta-analysis.
    Huang S; Huang Z; Huang X; Luo R; Liang W; Qin T
    Front Immunol; 2024; 15():1375136. PubMed ID: 39072325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.